Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 12;14(4):920.
doi: 10.3390/cancers14040920.

Effects of Endocrine Therapy on Cognitive Function in Patients with Breast Cancer: A Comprehensive Review

Lucy R Haggstrom  1 , Janette L Vardy  2   3 , Emma-Kate Carson  1   4 , Davendra Segara  5 , Elgene Lim  5   6 , Belinda E Kiely  1   4   7
Affiliations
Review

Effects of Endocrine Therapy on Cognitive Function in Patients with Breast Cancer: A Comprehensive Review

Lucy R Haggstrom et al. Cancers (Basel). .

Abstract

Endocrine therapy forms the backbone of systemic therapy for the majority of persons with early and late-stage breast cancer. However, the side effects can negatively affect quality of life, and impact treatment adherence and overall oncological outcomes. Adverse effects on cognition are common, underreported and challenging to manage. We aim to describe the nature, incidence, risk factors and underlying mechanisms of endocrine therapy-induced cognitive dysfunction. We conducted a comprehensive literature review of the studies reporting on cognitive dysfunction associated with endocrine therapies for breast cancer. We also summarise prevention and treatment strategies, and ongoing research. Given that patients are taking endocrine therapies for longer durations than ever before, it is essential that these side effects are managed pro-actively within a multi-disciplinary team in order to promote adherence to endocrine therapy and improve patients' quality of life.

Keywords: breast cancer; cognitive dysfunction; endocrine therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. DeSantis C.E., Bray F., Ferlay J., Lortet-Tieulent J., Anderson B.O., Jemal A. International Variation in Female Breast Cancer Incidence and Mortality Rates. Cancer Epidemiol. Biomarkers Prev. 2015;24:1495–1506. doi: 10.1158/1055-9965.EPI-15-0535. - DOI - PubMed
    1. The Global Cancer Observatory. International Agent for Research on Cancer Breast. [(accessed on 13 October 2021)]. Available online: https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf.
    1. Waks A.G., Winer E.P. Breast Cancer Treatment: A Review. JAMA. 2019;321:288–300. doi: 10.1001/jama.2018.19323. - DOI - PubMed
    1. Wojtyla C., Bertuccio P., Ciebiera M., La Vecchia C. Breast Cancer Mortality in the Americas and Australasia over the Period 1980–2017 with Predictions for 2025. Biology. 2021;10:814. doi: 10.3390/biology10080814. - DOI - PMC - PubMed
    1. Glassman D., Hignett S., Rehman S., Linforth R., Salhab M. Adjuvant Endocrine Therapy for Hormone-positive Breast Cancer, Focusing on Ovarian Suppression and Extended Treatment: An Update. Anticancer Res. 2017;37:5329–5341. doi: 10.21873/anticanres.11959. - DOI - PubMed

LinkOut - more resources